Robert Lebovics, MD
Otolaryngology · New York, NYNPI 1255428082
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,625 of the $13,913 with a category attached, or 69.2%. Amgen accounts for 93.0% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $6,791 and has fallen 99.8% since, to $17 in 2025. Among otolaryngology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $356.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$13K
- Ambu Inc.$337
- Inspire Medical Systems, Inc.$173
- Siemens Medical Solutions USA, Inc.$68
- Regeneron Healthcare Solutions, Inc.$65
- Atricure, Inc.$37
- plus $292 from 12 others
Across 2 payments — averaging $5430.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$11K
What the payments were for
- Consulting fees$9,62569%
- Speaking & faculty fees$3,30024%
- Food & beverage$9887%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $12,941 |
| Ambu Inc. | 5 | $337 |
| Inspire Medical Systems, Inc. | 6 | $173 |
| Siemens Medical Solutions USA, Inc. | 3 | $68 |
| Regeneron Healthcare Solutions, Inc. | 3 | $65 |
| Atricure, Inc. | 1 | $37 |
| Merck | 2 | $33 |
| GSK | 2 | $32 |
| United Therapeutics Corporation | 2 | $32 |
| Medtronic | 2 | $32 |
| Johnson & Johnson | 1 | $27 |
| Pulmonx Corporation | 1 | $23 |
| BD | 1 | $23 |
| Olympus America Inc. | 1 | $22 |
| TELA Bio, Inc. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavneos$12,925
How this compares
$13,913 in reported general payments places this provider in the 90th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 30 | $213 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in New York
- Roheen RaithathaNew York$830K
- Dennis KrausNew York$159K
- Anthony DelsignoreNew York$89K
- Satish GovindarajNew York$39K
- Lawrence LustigNew York$33K
- Justin GolubNew York$30K
- Brett MilesNew York$30K
- David HiltzikNew York$25K
- Milan AminNew York$23K
- Ashutosh KackerNew York$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.